Adamis Pharmaceuticals (NASDAQ:ADMP) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) in a research report issued on Friday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Adamis Pharmaceuticals Trading Down 4.4 %

Shares of Adamis Pharmaceuticals stock opened at $0.13 on Friday. The business has a 50-day moving average price of $0.21 and a two-hundred day moving average price of $0.21. Adamis Pharmaceuticals has a 1-year low of $0.12 and a 1-year high of $0.68.

Hedge Funds Weigh In On Adamis Pharmaceuticals

A hedge fund recently raised its stake in Adamis Pharmaceuticals stock. State Street Corp increased its stake in Adamis Pharmaceuticals Co. (NASDAQ:ADMP – Get Rating) by 13.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 475,373 shares of the specialty pharmaceutical company’s stock after acquiring an additional 55,168 shares during the quarter. State Street Corp owned 0.32% of Adamis Pharmaceuticals worth $271,000 at the end of the most recent reporting period. Institutional investors own 8.57% of the company’s stock.

About Adamis Pharmaceuticals

(Get Rating)

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets.